International Journal of Molecular Sciences · 2021 · 25 citations · 15 references
MedicineOncologyPharmacologyApoptosisChemotherapyMolecular OncologyApoptosis In CancerApoptosis ResistanceCancer Cell SignalingCombination ChemotherapyCytotoxic ChemotherapyC-jun N-terminal Kinase SignalingCancer Cell ApoptosisCell Cycle Arrest MechanismsChemotherapy-induced ApoptosisExtracellular Signal-regulated Kinase PathwayExtracellular Signal-regulated Kinase SignalingFucoidanJun N-terminal Kinase Signaling
This study investigated the roles of low-molecular-weight fucoidan (LMWF) in enhancing the anti-cancer effects of fluoropyrimidine-based chemotherapy. HCT116 and Caco-2 cells were treated with LMWF and 5-FU. Cell viability, cell cycle, apoptosis, and migration were analyzed in both cell types. Potential mechanisms underlying how LMWF enhances the anti-cancer effects of fluoropyrimidine-based chemotherapy were also explored. The cell viability of HCT116 and Caco-2 cells was significantly reduced after treatment with a LMWF-–5FU combination. In HCT116 cells, LMWF enhanced the suppressive effects of 5-FU on cell viability through the (1) induction of cell cycle arrest in the S phase and (2) late apoptosis mediated by the Jun-N-terminal kinase (JNK) signaling pathway. In Caco-2 cells, LMWF enhanced the suppressive effects of 5-FU on cell viability through both the c-mesenchymal–epithelial transition (MET)/Kirsten rat sarcoma virus (KRAS)/extracellular signal-regulated kinase (ERK) and the c-MET/phosphatidyl-inositol 3-kinases (PI3K)/protein kinase B (AKT) signaling pathways. Moreover, LMWF enhanced the suppressive effects of 5-FU on tumor cell migration through the c-MET/matrix metalloproteinase (MMP)-2 signaling pathway in both HCT116 and Caco-2 cells. Our results demonstrated that LMWF is a potential complementary therapy for enhancing the efficacies of fluoropyrimidine-based chemotherapy in colorectal cancers (CRCs) with the wild-type or mutated KRAS gene through different mechanisms. However, in vivo studies and in clinical trials are required in order to validate the results of the present study.
15
Christina Fitzmaurice · Journal of Clinical Oncology · 2018 · 1.7K citations · Full text
Medicine, Health Policy, Oncology +17
Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies
Kaja C. G. Berg, Peter W. Eide, Ina A. Eilertsen et al. · Molecular Cancer · 2017 · 395 citations · Full text
Subramanian Palanisamy, Manoharan Vinosha, Thangapandi Marudhupandi et al. · International Journal of Biological Macromolecules · 2017 · 265 citations